» Articles » PMID: 32872746

Weight Change and Microvascular Outcomes in Patients with New-onset Diabetes: a Nationwide Cohort Study

Overview
Specialty General Medicine
Date 2020 Sep 3
PMID 32872746
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: Because weight control is important in treatment of type 2 diabetes, it is essential to understand the associations between weight change and the risk of microvascular complications among patients with type 2 diabetes. We examined whether weight changes early after new-onset diabetes have an impact on the clinical outcomes of diabetic nephropathy and retinopathy.

Methods: Using the Korean National Health Insurance Service-National Health Screening Cohort database, 181,872 patients newly diagnosed with type 2 diabetes who were free of end-stage renal disease (ESRD) and proliferative diabetic retinopathy (PDR) during 2007 to 2012 were followed to the end of 2016. Weight change was defined as the difference in body weight from the time of diabetes diagnosis to 2 years later.

Results: We identified 180 cases of ESRD and 780 cases of PDR followed up for a median of 5.5 years from the index year at 2 years after diagnosis. Those with 5% to 10% weight gain showed a significantly higher hazard ratio (HR) for ESRD, compared with those with ≤ 5% weight change after adjusting for several confounding factors, including the baseline estimated glomerular filtration rate (HR, 1.75; 95% confidence interval [CI], 1.14 to 2.70). Those with ≥ 10% weight loss showed the lowest HR for PDR (HR, 0.52; 95% CI, 0.33 to 0.83), whereas those with ≥ 10% weight gain showed the highest HR for PDR (HR, 3.20; 95% CI, 2.51 to 4.08).

Conclusion: Weight gain after new-onset diabetes was associated with increased risk of ESRD and PDR whereas weight loss with decreased risk of PDR, but not ESRD.

Citing Articles

Blood pressure levels and risk of end-stage renal disease in patients with type 2 diabetes who underwent percutaneous coronary intervention: a nationwide population-based study.

Kim H, Park Y, Ko S, Cho Y, Kim H, Kim Y Sci Rep. 2025; 15(1):7832.

PMID: 40050367 PMC: 11885479. DOI: 10.1038/s41598-025-91835-x.


Trajectories of Body Mass Index and Risk for Diabetes Complications and All-Cause Mortality in Finnish Type 2 Diabetes Patients.

Wang Z, Lavikainen P, Wikstrom K, Laatikainen T Clin Epidemiol. 2024; 16:203-212.

PMID: 38567371 PMC: 10986625. DOI: 10.2147/CLEP.S450455.


Treat Obesity to Treat Type 2 Diabetes Mellitus.

Sulu C, Yumuk V Diabetes Ther. 2024; 15(3):611-622.

PMID: 38310627 PMC: 10942960. DOI: 10.1007/s13300-024-01536-3.


Duration of diabetes mellitus and risk of kidney and bladder cancer: a longitudinal nationwide cohort study.

Choi Y, Park Y, Hur K, Ha U, Hong S, Lee J Am J Cancer Res. 2022; 12(8):4050-4061.

PMID: 36119837 PMC: 9441993.


American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.

Blonde L, Umpierrez G, Reddy S, McGill J, Berga S, Bush M Endocr Pract. 2022; 28(10):923-1049.

PMID: 35963508 PMC: 10200071. DOI: 10.1016/j.eprac.2022.08.002.


References
1.
Jeng C, Hsieh Y, Yang C, Yang C, Lin C, Wang I . Diabetic Retinopathy in Patients with Diabetic Nephropathy: Development and Progression. PLoS One. 2016; 11(8):e0161897. PMC: 5001700. DOI: 10.1371/journal.pone.0161897. View

2.
Koh E, Kim M, Kim M, Han K, Shin S, Kwon H . Intra-individual variability in high density lipoprotein cholesterol and risk of end-stage renal disease: A nationwide population-based study. Atherosclerosis. 2019; 286:135-141. DOI: 10.1016/j.atherosclerosis.2019.05.018. View

3.
Dow C, Mancini F, Rajaobelina K, Boutron-Ruault M, Balkau B, Bonnet F . Diet and risk of diabetic retinopathy: a systematic review. Eur J Epidemiol. 2017; 33(2):141-156. DOI: 10.1007/s10654-017-0338-8. View

4.
Hsieh Y, Tsai M, Tu S, Hsieh M . Association of Abnormal Renal Profiles and Proliferative Diabetic Retinopathy and Diabetic Macular Edema in an Asian Population With Type 2 Diabetes. JAMA Ophthalmol. 2017; 136(1):68-74. PMC: 5833599. DOI: 10.1001/jamaophthalmol.2017.5202. View

5.
Whaley-Connell A, Sowers J . Obesity and kidney disease: from population to basic science and the search for new therapeutic targets. Kidney Int. 2017; 92(2):313-323. DOI: 10.1016/j.kint.2016.12.034. View